Boston scientific receives fda approval for expanded labeling of farapulse™ pulsed field ablation system

The farapulse pfa system now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation marlborough, mass. , july 7, 2025 /prnewswire/ -- boston scientific corporation (nyse: bsx) has received u.s. food and drug administration (fda) approval to expand the instructions for use (ifu) labeling for the farapulse™ pulsed field ablation (pfa) system.
BSX Ratings Summary
BSX Quant Ranking